Amgen seeks US FDA approval for Nplate to treat adults with immune thrombocytopenia

Amgen announced the submission of a Supplemental Biologics License Application (sBLA) to the US Food and Drug Administration (FDA) for Nplate (romiplostim) to include the treatment of adult patients with

More From BioPortfolio on "Amgen seeks US FDA approval for Nplate to treat adults with immune thrombocytopenia"